Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
3SBio ( (HK:1530) ) has issued an update.
3SBio Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Shenyang, China. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, declaration of a final dividend, and re-appointment of auditors. The meeting will also address resolutions related to the issuance of additional shares, which could impact the company’s capital structure and shareholder value.
The most recent analyst rating on (HK:1530) stock is a Buy with a HK$9.46 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
3SBio Inc. is a biotechnology company focused on the development, manufacturing, and marketing of biopharmaceutical products. The company operates primarily in the healthcare industry, providing innovative therapies for patients with unmet medical needs.
YTD Price Performance: 229.77%
Average Trading Volume: 58,591,287
Technical Sentiment Signal: Buy
Current Market Cap: HK$48.09B
For an in-depth examination of 1530 stock, go to TipRanks’ Stock Analysis page.